Jump to content

New CT enrolling now- Atezolizumab (Stage IV Squamous)


Recommended Posts

HI All,

Here is information on two new clinical trials that are recruiting.  Please feel free to share this link to make others aware! 



Currently Recruiting for these two Atezolizumab Trials:

IMpower 110 (GO29431):

A Comparative Study of Atezolizumab With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

This randomized, open-label study will evaluate the safety and efficacy of Atezolizumab compared with treatment with a platinum-based regimen (carboplatin or cisplatin per investigator discretion) + pemetrexed in PD-L1-selected, chemotherapy-naive patients with Stage IV NSCLC.


IMpower 111 (GO29432):

A Study of Atezolizumab Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer.

This randomized, open-label study is designed to evaluate and compare the safety and efficacy of Atezolizumab compared with treatment with gemcitabine + cisplatin or carboplatin in patients with chemotherapy-naive, Stage IV squamous non-small cell lung cancer (NSCLC).

For information about the trials online:  http://www.antipdl1clinicaltrials.com/hcp/antiPDL1_clinical_trial_info/lung-cancer


To Contact the Genentech Trial Information Support Line:


Phone: 1-888-662-6728  (US and Canada only)
Hours of Operation: 6am - 3pm PST Monday – Friday

Email Address: global.rochegenentechtrials@roche.com

Arin Assero

Senior Director, Global Stakeholder Relations

Cullari Communications Global



Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.